New Delhi: India is set to see the launch of Afrezza—the only rapid-acting, inhaled insulin to help control high blood sugar in adults with type 1 or type 2 diabetes—ten years after the ...

‘A breath of fresh air for #diabetes_management! Inhaled #insulin, #Afrezza, is now available in #India, thanks to #Cipla. #diabetes’ The company noted that Afrezza will start working in as ...

Mannkind Corporation expects to submit a request for a supplemental new drug application meeting to the US Food and Drug Administration for its inhaled human insulin (Afrezza Inhalation Powder).

“The availability of insulin to be inhaled through the lungs will provide a new and innovative option for patients with diabetes mellitus,” he added. Afrezza has been evaluated in over 70 ...

“The availability of Afrezza has the potential to help so many people in India living with diabetes in improving glycemic control via a non-injectable and convenient delivery of inhaled insulin ...

Afrezza (insulin human) Inhalation Powder is a rapid-acting inhaled human insulin indicated to improve glycemic control in adults with diabetes mellitus. Limitations of Use: Not recommended for ...

MannKind Corporation announced today that it plans to meet with the FDA to discuss a potential supplemental new drug application (sNDA) for its inhaled insulin product, Afrezza, following positive ...

The Afrezza-treated patients had a mean FEV1 ... in our more than 25-year history of pioneering the development of inhaled insulin and working to bring this new treatment option to children ...

“The availability of Afrezza has the potential to help so many people in India living with diabetes in improving glycemic control via a non-injectable and convenient delivery of inhaled insulin,” said ...